News

Attune Pharmaceuticals‘ ATN-249, an investigational kallikrein inhibitor for the prevention of swelling attacks in hereditary angioedema (HAE) patients, was found generally safe and well-tolerated in a Phase 1 clinical trial with healthy volunteers, the company announced. Findings from this first-in-human trial (ACTRN12618000430235) were also presented during the recent …

The case of a man with hereditary angioedema (HAE) who remained undiagnosed for 62 years underscores the importance of carefully evaluating not only the clinical data of suspected patients, but also their family history. Due to the diagnosis delay the patient…

Some mutations in the SERPING1 gene that cause hereditary angioedema (HAE) result in an abnormal form of the C1 inhibitor (C1-INH) that binds to and traps healthy C1-INH in cells, severely reducing the amount of protein available to prevent HAE attacks, a study shows. The study, “Dominant negative SERPING1…

Physicians in Canada need better education about the multiple biological assays used to diagnose hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE), which will increase their confidence and access to relevant tests, a study shows. The study, “The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey…

Researchers have developed a more cost-effective supporting diagnostic test for hereditary angioedema (HAE) to detect genetic changes that are otherwise missed by current standard methods. The study, “Gene mapping strategy for Alu elements rearrangements: Detection of new large deletions in the SERPING1 gene causing hereditary angioedema in Brazilian…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Asphyxiation caused by head and neck angioedema — swelling and fluid accumulation in the deeper layers of the skin — is rare, and most such deaths are due to bradykinin-mediated disease, a French study reported. In fact, bradykinin-mediated disease is 45 times more likely to be…

Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, making it the first antibody available in the EU for this indication. The European Commission’s decision comes shortly after the Committee for Medicinal Products…

Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 and older, a Phase 3 trial shows. The treatment also kept more patients attack-free during the 26-week study, reduced…

Long-term prevention with human formulations of the C1 esterase inhibitor — Cinryze or Haegarda — safely and effectively reduces the number of acute attacks in people with hereditary angioedema (HAE), but the therapies’ prices are too high, according to a report of the Institute for Clinical and Economic Review…